+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy

Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy

Gynecologic Oncology 79(3): 490-494

The aim of this study is to examine the patterns of failure after extended surgical staging and postoperative vaginal vault brachytherapy as the only adjuvant treatment in high-risk surgical Stage I patients with endometrial carcinoma. The records of all patients with endometrial carcinoma (adenocarcinoma or adenosquamous) receiving vaginal vault brachytherapy as the only adjuvant treatment from January 1989 to December 1997 were examined. A total of 489 patients were found. Of these, 133 had extended surgical staging. The study group consists of 77 surgical Stage I patients with Substages IBG3 and any grade IC. Recurrences were recorded as in the vagina, pelvis, or distant. The mean follow-up interval was 45 months (range 14 to 96 months). Eleven patients had recurrence (14%). Median time to recurrence was 15 months (range 6 to 56 months). Recurrences occurred in the vagina in 7, pelvis in 1, and distantly in 3 patients. Five of 7 vaginal recurrences occurred within 2 years. All patients with distant recurrence died from disease. One patient with pelvic recurrence is alive with disease. Only 1 patient with vaginal recurrence died from disease. Six patients with isolated recurrences in the vagina were successfully treated with radiotherapy with or without local excision. All 6 have no evidence of disease at follow-up (median survival 29 months, range 20 to 71 months). The vagina remains the most common site of recurrence for high-risk surgical Stage I patients treated with postoperative vaginal vault brachytherapy. Close follow-up in the first 2 years is essential to detect isolated vaginal recurrences. These are amenable to salvage treatment with good disease-free survival.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 010930481

Download citation: RISBibTeXText

PMID: 11104626

DOI: 10.1006/gyno.2000.6005

Related references

Postoperative vaginal vault brachytherapy for node-negative Stage II (occult) endometrial carcinoma. Gynecologic Oncology 81(2): 193-195, 2001

Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecologic Oncology 75(1): 103-107, 1999

Vaginal Vault Brachytherapy Alone As Adjuvant Treatment For Node-Negative Stage Ii Endometrial Cancer Manitoba Experience. Radiotherapy and Oncology 92: S45-S46, 2009

Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy. Oncology 96(5): 235-241, 2019

Disease-free survival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma. Gynecologic Oncology 110(3): 280-285, 2008

Stage II endometrial carcinoma: limiting post-operative radiotherapy to the vaginal vault in node-negative tumors. Gynecologic Oncology 98(3): 434-438, 2005

Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer. BrachyTherapy 7(2): 195-199, 2008

Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: Report of a prospective trial. International Journal of Radiation Oncology Biology Physics 38(2): 373-380, 1997

Assessing Efficacy of Adjuvant Vaginal Vault Brachytherapy Among Intermediate-Risk Stage I Endometrial Cancer Patients. International Journal of Radiation Oncology*biology*physics 84(3): S455-S456, 2012

Vaginal high dose rate brachytherapy alone in patients with intermediate- to high-risk stage I endometrial carcinoma after radical surgery. International Journal of Gynecological Cancer 18(6): 1294-1299, 2008

Single vaginal vault recurrences following endometrial carcinoma stage 1 treated by operation. Geburtshilfe und Frauenheilkunde 39(4): 300-303, 1979

High-risk surgical stage 1 endometrial cancer: Outcomes with vault brachytherapy alone. Gynecologic Oncology 89(2): 288-294, 2003

The vaginal stump recurrence rate in endometrial carcinoma in relation to the target volume of postoperative HDR-afterloading brachytherapy. Strahlentherapie und Onkologie 173(1): 13-17, 1997

Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I, intermediate- and high-risk cases of endometrium carcinoma. Journal of Contemporary BrachyTherapy 10(2): 105-114, 2018

High dose rate brachytherapy in the treatment of vaginal recurrence of endometrial carcinoma. Clinical & Investigative Medicine 15(4 Suppl.): A133, 1992